Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity

Eric D. Laing, Nusrat J. Epsi, Stephanie A. Richard, Emily C. Samuels, Wei Wang, Russell Vassell, Daniel F. Ewing, Rachel Herrup, Spencer L. Sterling, David A Lindholm, Eugene V. Millar, Ryan C. Maves, Derek T. Larson, Rhonda E. Colombo, Sharon Chi, Cristian Madar, Tahaniyat Lalani, Anuradha Ganesan, Anthony Fries, Christopher J. Colombo, Katrin Mende, Mark P. Simons, Kevin L. Schully, Carol D. Weiss, David R. Tribble, View ORCID ProfileBrian K. Agan, Simon D. Pollett, Christopher C. Broder, Timothy H. Burgess, for the EPICC Study team
doi: https://doi.org/10.1101/2021.04.27.21256207
Eric D. Laing
1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nusrat J. Epsi
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie A. Richard
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily C. Samuels
1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD USA
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Wang
4Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell Vassell
4Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel F. Ewing
5Biological Defense Research Directorate, Naval Medical Research Center-Fort Detrick, Frederick, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Herrup
4Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spencer L. Sterling
1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD USA
MpH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A Lindholm
6Brooke Army Medical Center, Fort Sam Houston, TX, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene V. Millar
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan C. Maves
7Naval Medical Center San Diego, San Diego, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek T. Larson
8Fort Belvoir Community Hospital, Fort Belvoir, VA, USA
DO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rhonda E. Colombo
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD USA
9Madigan Army Medical Center, Joint Base Lewis-McChord, WA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Chi
10Tripler Army Medical Center, Honolulu, HI, USA
DO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristian Madar
10Tripler Army Medical Center, Honolulu, HI, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tahaniyat Lalani
11Naval Medical Center Portsmouth, Portsmouth, VA, USA
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anuradha Ganesan
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD USA
12Walter Reed National Military Medical Center, Bethesda, MD
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Fries
13U.S. Air Force School of Aerospace Medicine, Dayton, Ohio, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Colombo
9Madigan Army Medical Center, Joint Base Lewis-McChord, WA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrin Mende
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD USA
6Brooke Army Medical Center, Fort Sam Houston, TX, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark P. Simons
1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin L. Schully
5Biological Defense Research Directorate, Naval Medical Research Center-Fort Detrick, Frederick, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol D. Weiss
4Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Tribble
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian K. Agan
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brian K. Agan
Simon D. Pollett
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD USA
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher C. Broder
1Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy H. Burgess
2Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: timothy.burgess@usuhs.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Importance The persistence of SARS-CoV-2 antibodies may be a predictive correlate of protection for both natural infections and vaccinations. Identifying predictors of robust antibody responses is important to evaluate the risk of re-infection / vaccine failure and may be translatable to vaccine effectiveness.

Objective To 1) determine the durability of anti-SARS-CoV-2 IgG and neutralizing antibodies in subjects who experienced mild and moderate to severe COVID-19, and 2) to evaluate the correlation of age and IgG responses to both endemic human seasonal coronaviruses (HCoVs) and SARS-CoV-2 according to infection outcome.

Design Longitudinal serum samples were collected from PCR-confirmed SARS-CoV-2 positive participants (U.S. active duty service members, dependents and military retirees, including a range of ages and demographics) who sought medical treatment at seven U.S. military hospitals from March 2020 to March 2021 and enrolled in a prospective observational cohort study.

Results We observed SARS-CoV-2 seropositivity in 100% of inpatients followed for six months (58/58) to one year (8/8), while we observed seroreversion in 5% (9/192) of outpatients six to ten months after symptom onset, and 18% (2/11) of outpatients followed for one year. Both outpatient and inpatient anti-SARS-CoV-2 binding-IgG responses had a half-life (T1/2) of >1000 days post-symptom onset. The magnitude of neutralizing antibodies (geometric mean titer, inpatients: 378 [246-580, 95% CI] versus outpatients: 83 [59-116, 95% CI]) and durability (inpatients: 65 [43-98, 95% CI] versus outpatients: 33 [26-40, 95% CI]) were associated with COVID-19 severity. Older age was a positive correlate with both higher IgG binding and neutralizing antibody levels when controlling for COVID-19 hospitalization status. We found no significant relationships between HCoV antibody responses and COVID-19 clinical outcomes, or the development of SARS-CoV-2 neutralizing antibodies.

Conclusions and Relevance This study demonstrates that humoral responses to SARS-CoV-2 infection are robust on longer time-scales, including those arising from milder infections.

However, the magnitude and durability of the antibody response after natural infection was lower and more variable in younger participants who did not require hospitalization for COVID-19. These findings support vaccination against SARS-CoV-2 in all suitable populations including those individuals that have recovered from natural infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This project has been funded by the Defense Health Program, U.S. DoD, under awards HU0001190002 and HU00012020067, and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under award HU00011920111 and Inter-Agency Agreement Y1-AI-5072.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The referenced human subjects protocol (IDCRP-085) was approved by the Uniformed Services University Institutional Review Board and participating sites. All subjects or their legally authorized representative provide written or verbal informed consent using approved documents and procedures; the consent forms include clauses allowing use of specimens for investigations including those conducted in this study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Back to top
PreviousNext
Posted May 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity
Eric D. Laing, Nusrat J. Epsi, Stephanie A. Richard, Emily C. Samuels, Wei Wang, Russell Vassell, Daniel F. Ewing, Rachel Herrup, Spencer L. Sterling, David A Lindholm, Eugene V. Millar, Ryan C. Maves, Derek T. Larson, Rhonda E. Colombo, Sharon Chi, Cristian Madar, Tahaniyat Lalani, Anuradha Ganesan, Anthony Fries, Christopher J. Colombo, Katrin Mende, Mark P. Simons, Kevin L. Schully, Carol D. Weiss, David R. Tribble, Brian K. Agan, Simon D. Pollett, Christopher C. Broder, Timothy H. Burgess, for the EPICC Study team
medRxiv 2021.04.27.21256207; doi: https://doi.org/10.1101/2021.04.27.21256207
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity
Eric D. Laing, Nusrat J. Epsi, Stephanie A. Richard, Emily C. Samuels, Wei Wang, Russell Vassell, Daniel F. Ewing, Rachel Herrup, Spencer L. Sterling, David A Lindholm, Eugene V. Millar, Ryan C. Maves, Derek T. Larson, Rhonda E. Colombo, Sharon Chi, Cristian Madar, Tahaniyat Lalani, Anuradha Ganesan, Anthony Fries, Christopher J. Colombo, Katrin Mende, Mark P. Simons, Kevin L. Schully, Carol D. Weiss, David R. Tribble, Brian K. Agan, Simon D. Pollett, Christopher C. Broder, Timothy H. Burgess, for the EPICC Study team
medRxiv 2021.04.27.21256207; doi: https://doi.org/10.1101/2021.04.27.21256207

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (551)
  • Anesthesia (135)
  • Cardiovascular Medicine (1751)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (656)
  • Epidemiology (10790)
  • Forensic Medicine (8)
  • Gastroenterology (586)
  • Genetic and Genomic Medicine (2939)
  • Geriatric Medicine (287)
  • Health Economics (532)
  • Health Informatics (1921)
  • Health Policy (834)
  • Health Systems and Quality Improvement (744)
  • Hematology (291)
  • HIV/AIDS (628)
  • Infectious Diseases (except HIV/AIDS) (12509)
  • Intensive Care and Critical Care Medicine (687)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2789)
  • Nursing (151)
  • Nutrition (432)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1460)
  • Ophthalmology (443)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (363)
  • Primary Care Research (336)
  • Psychiatry and Clinical Psychology (2635)
  • Public and Global Health (5349)
  • Radiology and Imaging (1008)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (725)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)